文献速递免疫规划卫生政策与健康促进

发展中国家疫苗生产商技术能力对全球免疫规划的影响

Developing-country vaccine manufacturers' technical capabilities can make a difference in global immunization.
PubMed 文献 · Vaccine · 2021-08-03

发展中国家疫苗生产商网络(DCVMN)成员积极参与新冠疫苗研发,截至2020年12月29日有18家成员有临床前或临床试验疫苗,其中3家进入III期。一项121题调查评估了41家成员的生产能力,显示其在重组技术、细胞培养和灌装方面具备较强能力,超50%产能可专用于新冠疫苗生产。

要点

  • DCVMN成员具备重组技术、哺乳动物细胞及微生物酵母表达系统等疫苗生产能力。
  • Vero和CHO细胞培养及大规模灌装能力突出,超50%产能可转用于新冠疫苗。

核心结论

  • DCVMN成员生产商具备较强的疫苗生产技术能力,可在全球免疫规划中发挥关键作用。

研究设计与样本

  • 向41家DCVMN成员发放121题调查问卷,评估技术平台、细胞培养、灌装及产能专用准备。

主要发现

  • 18家成员有新冠疫苗处于临床前或临床试验,其中3家进入III期。
  • 成员在重组技术、哺乳动物细胞、微生物和酵母表达系统方面具备强生产能力。
  • 细胞培养能力覆盖多种细胞类型,Vero和CHO细胞制造能力突出。
  • 抽样生产商报告超50%疫苗产能可专用于新冠疫苗生产。

临床怎么用

  • 可依托DCVMN成员的大规模生产能力及技术平台,加速新冠疫苗全球供应与免疫规划实施。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Members of the Developing Countries Vaccine Manufacturers' Network (DCVMN) have been actively engaged in the development of COVID-19 vaccine candidates. According to the WHO COVID-19 vaccine landscape updated on 29 December 2020, 18 member manufacturers had vaccines in preclinical or clinical trials, including three members with candidates in Phase III trials. Once successful candidates have been identified there will be a need for large scale vaccine manufacturing and supply, in which DCVMN member manufacturers can play a key role. In an internal survey in 2019, DCVMN members reported the capability to supply over 3.5 billion vaccine doses annually, and the provision of over 50 distinct vaccines to 170 countries. To describe the capabilities of DCVMN member manufacturers more precisely, a 121-question survey was circulated to 41 Network members. The survey assessed the manufacturers' capabilities in utilizing various technology platforms, cell cultures and filling technologies, in addition to their capacities for manufacturing drug products. The survey also evaluated manufacturers' preparedness to dedicate existing capacities to COVID-19 vaccine production. Results revealed that sampled manufacturers have strong capabilities for manufacturing vaccines based on recombinant technologies, particularly with mammalian cells, and microbial and yeast expression systems. Capabilities in utilizing cell cultures were distributed across multiple cell types, however manufacturing capacities with Vero and CHO cells were prominent. Formulating and filling findings illustrated further large-scale capabilities of Network members. Sampled manufacturers reported that over 50% of their capacity for vaccine manufacturing could be dedicated to COVID-19 vaccine production.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Hayman B, Dennehy M. Developing-country vaccine manufacturers' technical capabilities can make a difference in global immunization. Vaccine. 2021. PMID: 34362602. doi:10.1016/j.vaccine.2021.07.044

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。